| Literature DB >> 32200663 |
Kevin J Clerkin1, Justin A Fried1, Jayant Raikhelkar1, Gabriel Sayer1, Jan M Griffin1, Amirali Masoumi1, Sneha S Jain1, Daniel Burkhoff1, Deepa Kumaraiah1, LeRoy Rabbani1, Allan Schwartz1, Nir Uriel1.
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.Entities:
Keywords: COVID-19; cardiovascular diseases; pandemics; severe acute respiratory syndrome coronavirus 2
Mesh:
Substances:
Year: 2020 PMID: 32200663 DOI: 10.1161/CIRCULATIONAHA.120.046941
Source DB: PubMed Journal: Circulation ISSN: 0009-7322 Impact factor: 29.690